Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T17:08:00.265Z.
Calculation as of: 2026-10-06T17:08:00.265Z.
Quote observation: 2026-10-05T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840
PEG RATIO
N/A
MiniMed Group, Inc.
Market Cap
$560.00M
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| MiniMed Group, Inc. (MMEDV) | $560.00M | N/A |
| CytomX Therapeutics, Inc. (CTMX)vs › | $560.91M | N/A |
| CorMedix Inc. (CRMD)vs › | $564.46M | N/A |
| Aquestive Therapeutics, Inc. (AQST)vs › | $570.25M | N/A |
| Shattuck Labs, Inc. (STTK)vs › | $543.14M | N/A |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $541.90M | N/A |
| Nuvectis Pharma, Inc. (NVCT)vs › | $537.90M | N/A |
| ProKidney Corp. (PROK)vs › | $536.32M | N/A |
| Delcath Systems, Inc. (DCTH)vs › | $536.12M | N/A |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $535.38M | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
